
Colgate-Palmolive (CL) Stock Forecast & Price Target
Colgate-Palmolive (CL) Analyst Ratings
Bulls say
Colgate-Palmolive is supported by a high-quality global portfolio, with international sales near 70% of revenue, nearly half from emerging markets, and Hill’s contributing almost one-fourth of sales through premium pet nutrition channels. Recent results strengthened the bull case: organic sales grew 3.6% on 5.4% emerging-market growth, while operating leverage from 1.7% volume/mix lifted gross margin and EPS, prompting a 2026 EPS forecast of 6% growth and gross margin of 60.4%. The outlook remains constructive because productivity and pricing are offsetting roughly $300M in raw-material headwinds, and management sees early share improvement in North America alongside continued strength in emerging markets and Hill’s.
Bears say
Colgate-Palmolive is facing a negative outlook because its North America business remains a growth drag, with Q3 organic sales down 1.6%, volumes down 3%, and operating margin falling 210 bps to 19.5%, the worst of any division. Competitive pressure from P&G and Haleon, combined with self-inflicted pricing and promotion missteps, has exposed innovation gaps in whitening and premium therapeutics, while Colgate Total’s 2025 relaunch appears late relative to rivals’ entrenched positions. At the same time, management expects commodity, logistics, and FX headwinds to persist into next year and through 1H27, limiting margin durability even after 90 bps of Q3 gross margin expansion.
This aggregate rating is based on analysts' research of Colgate-Palmolive and is not a guaranteed prediction by Public.com or investment advice.
Colgate-Palmolive (CL) Analyst Forecast & Price Prediction
Start investing in Colgate-Palmolive (CL)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Colgate-Palmolive (CL) Forecast
Colgate-Palmolive (CL) Analyst Forecast & Price Prediction
Start investing in Colgate-Palmolive (CL)
Order type
Buy in
Order amount
Est. shares
0 shares